Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 11 (2019)

Design and development of gentamicin based novel nano composite against multi drug resistant bacteria

Anindita Biswas, PW Ramteke and Himanshu Pandey
Drug resistance by bacteria makes treatment procedure expensive, difficult and time consuming. Countries where antibiotic could be purchased without prescription, there situations are deadlier and with the increased rate of travelling throughout the globe multidrug resistant bacteria have reached every nook and corner of civilization. That going to lead us to the age where a simple sore throat might cause life risk, like pre-antibiotic era. In the recent years 2D carbon nano composite based drugs have proved its potential, against microbial infections due to their high pay load, and site specific drug delivery. Novel nano composite: combination of-protein synthesis inhibitor- gentamicin, conjugated with efficient nano carrier- graphene could result better in antibiotic resistance with the improved pharmacokinetics at intended site, against topical infection caused by drug resistant E. coli 1614. This study was primarily based on two stages: preconjugation studies including FTIR analysis. There nine different conjugates of gentamicin loaded graphene have been developed and further solid state characterization showed no significant interaction of the drug with the chosen nano-carrier used in conjugate that would lead to cumulative antibacterial activity of drug and carrier. In second stage was to looking for LD50 determination through colony count method. LD50 determination study concluded that, gentamicin loaded graphene is an excellent antibacterial agent against E. coli 1614 with a LD50 of as low as 9.4 µg/ml.
Pages: 296-301  |  565 Views  89 Downloads

The Pharma Innovation Journal
How to cite this article:
Anindita Biswas, PW Ramteke, Himanshu Pandey. Design and development of gentamicin based novel nano composite against multi drug resistant bacteria. Pharma Innovation 2019;8(11):296-301.

Call for book chapter